You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

How to Prescribe

A complete once-daily regimen in the smallest single pill, taken with a meal12.

*Pill size is 14mm, image may not reflect actual size

JULUCA is for the treatment of HIV-1 in patients who want to reduce their ARV exposure and1:

Drug-Drug Interactions1

  • No known interactions with contraceptives, antihypertensives, statins, PDE-5 inhibitors
  • Contraindicated:
    • Proton pump inhbitors
    • Dofetilide
    • Rifampicin, rifapentine
    • Carbamazepine, oxcarbazepine, phenobarbital, phenytoin
    • Systemic dexamethasone, except as a single dose treatment
    • St John's wort

Other dosing considerations:

  • Juluca should not be administered with other antiretroviral medicinal products for the treatment of HIV
  • Dose separation for antacids (6 hours before or 4 hours after) and H2-antagonists (12 hours before or 4 hours after)
  • Dose adjustment of metformin may be required
  • Juluca contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine
  • Co-administer multivitamins or calcium/iron supplements and Juluca together with a meal.  Alternatively, dose separation for multivitamins or calcium/iron supplements (6 hours before or 4 hours after)
  • When Juluca is co-administered with rifabutin, an additional RPV 25 mg tablet should be taken once daily at the same time as Juluca

Pregnancy:

  • The use of Juluca during pregnancy is not recommended.
  • Women of childbearing potential (WOCBP) should undergo pregnancy testing before initiation of Juluca. WOCBP who are taking Juluca should use effective contraception throughout treatment.1

For further information, please see the JULUCA Prescribing Information.

References:

  1. JULUCA Summary of Product Characteristics. Avialble from: www.medicines.ie. Last accessed: March 2019.
  2. Data on File – STR Size Comparison, January 2019.

Adverse events should be reported directly to the HPRA; Freepost, Pharmacovigilance Section, Health Products Regulatory Authority, Earlsfort Terrace, Dublin 2, Tel: +353 1 676 4971 medsafety@hpra.ie . Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

▼ These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Trade marks are owned by or licensed to the ViiV Healthcare group of companies.